Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment
von
, Uhr
“Defensins are conceptually ideal for defense against different viral infections” WAKEFIELD, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company is exploring its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus treatment. Over the